Eronib150 mg

Eronib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used in oncology. Its use is guided by the strength of clinical evidence and biomarker (EGFR mutation) status.

Established/FDA-approved indications

• Non-small cell lung cancer (NSCLC): First-line, maintenance, or second-line and beyond treatment of metastatic NSCLC in patients whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test. Eronib is not recommended in combination with platinum-based chemotherapy.
• Pancreatic cancer: First-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer, used in combination with gemcitabine (a combination-therapy requirement, not monotherapy).

Important note

Eronib is a specialist oncology medicine. It must only be prescribed, dosed, and monitored by a qualified oncologist, with EGFR mutation testing performed before starting therapy for NSCLC.

Each film-coated tablet contains Erlotinib (as erlotinib hydrochloride) 100 mg or 150 mg as the active ingredient, along with standard pharmaceutical excipients such as lactose, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, magnesium stearate, and a film-coating system.

Eronib is a small-molecule, reversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, taken by mouth. It is used as targeted therapy for certain EGFR mutation-positive non-small cell lung cancers and, in combination with gemcitabine, for advanced pancreatic cancer. As a targeted anti-cancer agent, Eronib is dispensed and used strictly under the supervision of an oncology specialist, with regular monitoring for efficacy and toxicity.

Eronib belongs to the therapeutic class of antineoplastic agents, specifically the EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors, a subclass of targeted, small-molecule anti-cancer drugs.

Erlotinib works by reversibly binding to the intracellular tyrosine kinase domain of the epidermal growth factor receptor (EGFR/HER1), blocking autophosphorylation and downstream signaling pathways (such as RAS/RAF/MEK/ERK and PI3K/AKT) that drive tumor cell proliferation, survival, and angiogenesis. Tumors harboring activating EGFR exon 19 deletion or exon 21 L858R mutations are particularly sensitive to this inhibition, which is why mutation testing is required before use. After oral administration, Erlotinib absorption is variable and significantly increased by food; it is highly protein bound, extensively metabolized in the liver primarily by CYP3A4 (and to a lesser extent CYP1A2), and eliminated mainly via bile/feces with a mean elimination half-life of about 36 hours.

Take Eronib tablets whole with water, exactly as prescribed by the treating oncologist. Take on an empty stomach - at least 1 hour before or 2 hours after eating - because food significantly increases absorption and can alter drug exposure. Take at approximately the same time each day. Do not crush, split, or chew the tablet unless specifically advised. Do not stop or change the dose without consulting the prescribing physician.

Eronib is primarily metabolized by CYP3A4, making it prone to clinically significant drug interactions.

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, atazanavir): increase Eronib plasma levels and toxicity risk; dose reduction or avoidance is recommended.
• Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's Wort): decrease Eronib levels and may reduce efficacy; alternative agents or dose increase (with close monitoring) may be needed.
• Cigarette smoking: Induces CYP1A2 and significantly reduces Eronib plasma concentrations (by roughly half); smokers may require higher doses under close physician supervision, and smoking cessation should be strongly advised before and during treatment.
• Acid-reducing agents (proton pump inhibitors, H2-receptor antagonists, antacids): Reduce Eronib solubility and absorption because it requires an acidic environment; concomitant proton pump inhibitor use should be avoided if possible, and if an H2-blocker or antacid is needed, dosing should be separated by several hours from Eronib.
• Warfarin and other CYP2C9-metabolized anticoagulants: Co-administration has been associated with increased INR and bleeding events; monitor prothrombin time/INR regularly.
• NSAIDs and corticosteroids: May increase the risk of gastrointestinal perforation when used with Eronib (see Precautions and Warnings).

Very common side effects (occurring in a large proportion of patients) include:

• Acneiform (acne-like) skin rash
• Diarrhea
• Loss of appetite (anorexia)
• Fatigue and weakness
• Shortness of breath (dyspnea) and cough
• Nausea and vomiting
• Dry skin, itching
• Mouth sores (stomatitis)

Less common but serious reactions include severe or dose-limiting diarrhea, liver enzyme elevations, and eye irritation/dry eyes. For rare but potentially life-threatening reactions such as interstitial lung disease, severe hepatotoxicity, gastrointestinal perforation, and severe skin/eye reactions, see Precautions and Warnings. Patients should promptly report any new or worsening breathlessness, cough, fever, yellowing of skin/eyes, severe abdominal pain, severe rash, or eye pain to their oncologist.

Eronib can cause fetal harm and carries a significant teratogenic risk based on animal reproduction studies showing embryo-fetal toxicity and lethality. Eronib should not be used during pregnancy; if it must be considered, it should be used only if clearly needed and the potential benefit justifies the potential risk to the fetus, and only under close specialist supervision. Females of reproductive potential must use effective, non-hormonal contraception during treatment and for at least one month after the final dose; male patients with female partners of reproductive potential should also use effective contraception. Breastfeeding is not recommended during treatment with Eronib and for at least 2 weeks after the final dose, due to the potential for serious adverse effects in a nursing infant. Always consult a physician before considering pregnancy, during pregnancy, or while breastfeeding.

Interstitial lung disease (ILD)-like events

Serious, and sometimes fatal, ILD-like events (including pneumonitis) have occurred with Eronib. Patients should be monitored for new or worsening unexplained shortness of breath, cough, or fever; Eronib should be withheld immediately and pending diagnostic evaluation, and permanently discontinued if ILD is confirmed.

Hepatotoxicity and hepatic failure

Cases of hepatic failure, including some with fatal outcome, have been reported, particularly in patients with pre-existing hepatic impairment. Liver function tests should be monitored periodically; Eronib should be interrupted or discontinued if severe changes in liver function occur.

Gastrointestinal perforation

Rare but serious cases of GI perforation, sometimes fatal, have occurred, with increased risk in patients also taking corticosteroids, NSAIDs, or anti-angiogenic agents, or with a history of peptic ulcer disease or diverticular disease. Eronib should be permanently discontinued if perforation occurs.

Diarrhea

Diarrhea is common and can be severe or dose-limiting, occasionally leading to dehydration and electrolyte disturbances. It should be managed early with antidiarrheal treatment, and dose reduction, interruption, or discontinuation may be required for severe or persistent cases.

Dermatologic toxicity

Acneiform rash is very common and can be severe enough to require dose reduction, interruption, or discontinuation. Rare bullous, blistering, and exfoliative skin conditions, some resembling Stevens-Johnson syndrome/toxic epidermal necrolysis, have also been reported and require permanent discontinuation.

Ocular disorders

Corneal perforation or ulceration (sometimes with concurrent abnormal eyelash growth or severe keratitis) has been reported rarely. Patients with new or worsening eye symptoms should be evaluated promptly, and Eronib interrupted or discontinued if corneal perforation, ulceration, or severe keratitis is confirmed.

Cardiovascular and cerebrovascular events

Cases of myocardial infarction/ischemia, cerebrovascular accident, and microangiopathic hemolytic anemia with thrombocytopenia have been reported, particularly in patients receiving Eronib with gemcitabine for pancreatic cancer.

Renal failure

Renal failure or insufficiency, sometimes with electrolyte abnormalities, has been reported, especially in patients experiencing dehydration from diarrhea, vomiting, or anorexia; renal function and electrolytes should be monitored.

Elevated INR with warfarin

Regular monitoring of prothrombin time/INR is recommended in patients on concomitant warfarin therapy.

Smoking

Cigarette smoking reduces Eronib plasma levels; patients should be strongly advised to stop smoking before and during treatment, and dose adjustment under physician guidance may be needed for smokers (see Interactions).

Limited data are available on Eronib overdose. Reported effects of overdosage may include worsening of known adverse reactions such as severe diarrhea, rash, and liver enzyme elevation. There is no specific antidote for Eronib overdose. In case of suspected overdose, Eronib should be withheld, and the patient should seek immediate medical attention or contact emergency services/poison control for supportive and symptomatic management under medical supervision.

Store at room temperature (below 30°C), protected from light and moisture. Keep out of reach of children.

Hepatic impairment

Use with caution; increased risk of hepatotoxicity in patients with pre-existing hepatic impairment. Dose adjustment, interruption, or avoidance may be necessary depending on severity (see Dosage and Administration).

Renal impairment

Limited clinical data; use with caution and appropriate monitoring, particularly watching for dehydration-related renal complications.

Elderly patients

No overall differences in effectiveness have been reported between elderly and younger patients, but elderly patients may be more susceptible to certain adverse effects; monitor closely.

Smokers

Smoking reduces Eronib exposure; dose adjustment under specialist supervision and smoking cessation counseling are recommended (see Interactions).

Patients with EGFR mutation-negative or unknown tumors

Eronib should not be used for NSCLC unless EGFR exon 19 deletion or exon 21 (L858R) mutation status has been confirmed by an approved test, as benefit has not been established in mutation-negative disease.

Treatment with Eronib is generally continued until disease progression, unacceptable toxicity, or as otherwise directed by the treating oncologist. There is no fixed treatment duration; ongoing therapy requires periodic clinical, radiological, and laboratory reassessment.

Antineoplastic agent; EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor; targeted small-molecule anti-cancer therapy.

Erlotinib reversibly inhibits the tyrosine kinase activity associated with the epidermal growth factor receptor (EGFR/HER1) by binding at the ATP-binding site of the intracellular kinase domain. This blocks receptor autophosphorylation and interrupts downstream EGFR-mediated signaling cascades that promote tumor cell proliferation, survival, and invasion, resulting in reduced tumor growth in EGFR mutation-driven cancers.

D

The safety and effectiveness of Eronib in pediatric patients have not been established. Clinical studies of Eronib in children, including in pediatric brain tumors (ependymoma), have not demonstrated efficacy. Eronib is not recommended for use in children.